OAC monotherapy reduced major bleeding or CRNB by 52% (HR 0.47; 95% CI 0.30-0.75; p=0.001) compared with OAC plus APT in patients with AF and prior PCI with DES, with similar major ischemia.
Meta-Analysis (n=2,570)
Does oral anticoagulation monotherapy reduce bleeding or ischemic events compared to combination antithrombotic therapy in patients with atrial fibrillation and coronary artery disease following percutaneous coronary intervention with a drug-eluting stent?
In patients with AF and prior PCI with DES, OAC monotherapy significantly reduces bleeding without increasing ischemic events compared to OAC plus single antiplatelet therapy.
Hazard Ratio: 0.94 (95% CI 0.65–1.36)
p-value: p=0.75
Abstract Background Oral anticoagulation (OAC) and antiplatelet therapy (APT) represent a well-established preventative strategy against stroke, stent-related, and coronary ischemic events in patients with atrial fibrillation (AF) and coronary artery disease (CAD) following percutaneous coronary intervention (PCI). Less is known about the efficacy and safety of OAC as monotherapy compared with combined antithrombotic therapy in the subgroup of patients with drug-eluting stent (DES) implantation. Purpose To investigate whether deescalating from combination therapy of OAC with single APT to OAC monotherapy provides similar protection from major ischemic and bleeding endpoints in patients with AF and stable CAD following DES implantation. Methods We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) that compared OAC monotherapy (vitamin K antagonist or direct oral anticoagulant) with combination antithrombotic therapy of OAC plus single APT in patients with AF and CAD who underwent PCI with DES and reported the efficacy and safety composite outcomes of mortality, ischemia (myocardial infarction, stroke, or systemic embolism), and major bleeding or clinically relevant bleeding (CRNB). Cochrane's Review Manager Version 7.12.0 (RevMan, 2024) was used for statistical analysis to estimate pooled effects of hazard ratio (HR) with 95% confidence intervals (CI) under a random-effects model. Heterogeneity was examined with I² statistics. Results We included four RCTs comprising a total of 2570 patients, of whom 1302 (51%) were treated with OAC monotherapy, and the remaining 1268 (49%) were treated with combination therapy of OAC+APT. Median follow-up ranged from 12 to 30 months. There was no statistically significant difference in the efficacy endpoints of major ischemic composite (HR 0.94; 95% CI 0.65 to 1.36; p=0.75; Figure 1A) and the net clinical composite (HR 0.77; 95% CI 0.37 to 1.60; p=0.49; Figure 1B) between OAC monotherapy and OAC+APT combination therapy. However, there was a statistically significant reduction in the safety endpoint composite of major bleeding or CRNB with OAC monotherapy (HR 0.47; 95% CI 0.30 to 0.75; p=0.001; Figure 2A) compared with OAC+APT combination therapy, which was consistent in a sensitivity analysis of patients treated with predominantly new-generation DES (HR 0.38; 95% CI 0.25 to 0.59; p0.0001; Figure 2B). Conclusion Among patients with AF and prior PCI with DES implantation, OAC monotherapy statistically significantly reduced major bleeding or CRNB endpoint by 52% compared with combined antithrombotic therapy, but there was no significant difference between groups in terms of major ischemia or net clinical benefit.OAC Figure 1For image description, please refer to the figure legend and surrounding text. OAC Figure 2For image description, please refer to the figure legend and surrounding text.
Begic et al. (Mon,) conducted a meta-analysis in Atrial fibrillation and coronary artery disease following PCI with DES (n=2,570). Oral anticoagulation (OAC) monotherapy vs. Combination therapy of OAC plus single antiplatelet therapy (APT) was evaluated on Major ischemic composite (HR 0.94, 95% CI 0.65 to 1.36, p=0.75). OAC monotherapy reduced major bleeding or CRNB by 52% (HR 0.47; 95% CI 0.30-0.75; p=0.001) compared with OAC plus APT in patients with AF and prior PCI with DES, with similar major ischemia.